The author writes, “Microsoft has good news for anyone with corner office ambitions. In the future we’re all going to be ...

Panelists discuss how newer urinary tract infection (UTI) therapies such as pivmecillinam, sulopenem etzadroxil/probenecid, and gepotidacin demonstrate significantly lower resistance rates (below 5%) ...